Top

Published in:

01-09-2018 | ORIGINAL ARTICLE

Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma

Authors: Kenji Nakagawa, Takahiro Akahori, Satoshi Nishiwada, Minako Nagai, Kota Nakamura, Toshihiro Tanaka, Tetsuro Tamamoto, Chiho Ohbayashi, Masatoshi Hasegawa, Kimihiko Kichikawa, Naoya Ikeda, Masayuki Sho

Published in: Langenbeck's Archives of Surgery | Issue 6/2018

Abstract

Purpose

Recent advances in multidisciplinary treatments are improving the postoperative prognosis of pancreatic ductal adenocarcinoma (PDAC). However, the prognosis even after potentially curative resection remains poor. The aim of this study was to identify the clinical and pathological features of actual 5-year survivors under current circumstances.

Methods

A total of 128 patients who underwent pancreatectomy for PDAC at our institution between January 2006 and December 2011 were retrospectively analyzed.

Results

The actual 5-year overall survival rate for all patients was 30.9%, with a median survival time of 33.1 months. Of 128 patients, 25 (19.5%) survived for 5 years after surgery without disease recurrence. A univariate analysis showed that the pretreatment serum CA19–9 value, tumor depth, lymph node metastasis, and UICC stage at resection were significant predictive factors for the actual long-term survival. A multivariate analysis showed that a pretreatment serum CA19–9 value ≥ 110 U/mL was a significant unfavorable prognostic indicator. In addition, all subjects in the 5-year survival group completed adjuvant chemotherapy. The recurrence rate in the liver was significantly lower and that in the lung significantly higher in the long-term survival group than in the short-term survival group.

Conclusions

The factors contributing to the long-term survival of PDAC were the pretreatment CA19–9 value and the completion of adjuvant chemotherapy. To achieve the actual long-term survival and cure after pancreatectomy for pancreatic cancer, further treatment strategies enhancing the completion rate of adjuvant chemotherapy are required.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107 CrossRef

Hirata K, Sato T, Mukaiya M, Yamashiro K, Kimura M, Sasaki K, Denno R (1997) Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132(7):771–776 discussion 777CrossRef

Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Sur 91(5):586–594. https://doi.org/10.1002/bjs.4484 CrossRef

Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K (2014) Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 12:360. https://doi.org/10.1186/1477-7819-12-360 CrossRefPubMedPubMedCentral

Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247(3):456–462. https://doi.org/10.1097/SLA.0b013e3181613142 CrossRefPubMed

Perysinakis I, Avlonitis S, Georgiadou D, Tsipras H, Margaris I (2015) Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer. ANZ J Sur 85(3):183–186. https://doi.org/10.1111/ans.12422 CrossRef

Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA (2017) Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol 24(6):1722–1730. https://doi.org/10.1245/s10434-016-5716-z CrossRefPubMed

Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 34(8):1908–1915. https://doi.org/10.1007/s00268-010-0570-9 CrossRefPubMed

Han SH, Heo JS, Choi SH, Choi DW, Han IW, Han S, You YH (2017) Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. Int J Surg 40:68–72. https://doi.org/10.1016/j.ijsu.2017.02.007 CrossRefPubMed

10.

Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointestinal Surg 12(4):701–706. https://doi.org/10.1007/s11605-007-0384-8 CrossRef

11.

Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836–847. https://doi.org/10.1245/s10434-008-0295-2 CrossRefPubMedPubMedCentral

12.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2 CrossRefPubMed

13.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRef

14.

Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J, Yamato I, Hokuto D, Nishiofuku H, Marugami N, Kanehiro H, Kichikawa K, Nakajima Y (2011) Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 18(2):235–239; discussion 239-240. https://doi.org/10.1007/s00534-010-0336-7 CrossRefPubMed

15.

Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, Nishiofuku H, Marugami N, Enomonoto Y, Kasai T, Hasegawa M, Kichikawa K, Nakajima Y (2013) Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 20(2):197–205. https://doi.org/10.1007/s00534-012-0532-8 CrossRefPubMed

16.

Hashimoto A, Tanaka T, Sho M, Nishiofuku H, Masada T, Sato T, Marugami N, Anai H, Sakaguchi H, Kanno M, Tamamoto T, Hasegawa M, Nakajima Y, Kichikawa K (2016) Adjuvant hepatic arterial infusion chemotherapy after resection for pancreatic cancer using coaxial catheter-port system compared with conventional system. Cardiovasc Intervent Radiol 39(6):831–839. https://doi.org/10.1007/s00270-016-1292-7 CrossRefPubMed

17.

Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40(4):549–558. doi:https://doi.org/10.1016/j.ejca.2003.10.026 CrossRef

18.

Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH (2006) Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32(3):271–275. https://doi.org/10.1097/01.mpa.0000202953.87740.93 CrossRefPubMed

19.

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210; discussion 1210-1. https://doi.org/10.1016/j.gassur.2006.08.018 CrossRefPubMed

20.

Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43–S49. https://doi.org/10.1016/j.surg.2012.05.020 CrossRefPubMedPubMedCentral

21.

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277. https://doi.org/10.1001/jama.297.3.267 CrossRefPubMed

22.

Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 101(6):908–915. https://doi.org/10.1038/sj.bjc.6605256 CrossRefPubMedPubMedCentral

23.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081. https://doi.org/10.1001/jama.2010.1275 CrossRefPubMed

24.

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257. https://doi.org/10.1016/s0140-6736(16)30583-9 CrossRefPubMed

25.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825. https://doi.org/10.1056/NEJMoa1011923 CrossRefPubMed

26.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369 CrossRef

27.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545–557. https://doi.org/10.1016/s0140-6736(15)00986-1 CrossRefPubMed

28.

Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH (2016) Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy? J Surg Oncol 114(5):587–596. https://doi.org/10.1002/jso.24375 CrossRefPubMed

29.

Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP (2016) Outcomes of a clinical pathway for borderline resectable pancreatic cancer. Ann Surg Oncol 23(4):1371–1379. https://doi.org/10.1245/s10434-015-5006-1 CrossRefPubMed

30.

Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Tamamoto T, Nishiofuku H, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y (2015a) Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbeck's Arch Surg 400(4):477–485. https://doi.org/10.1007/s00423-015-1304-0 CrossRef

31.

Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y (2015b) Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci 22(7):563–570. https://doi.org/10.1002/jhbp.258 CrossRefPubMed

32.

Takahashi H, Akita H, Tomokuni A, Kobayashi S, Ohigashi H, Fijiwara Y, Yano M, Sakon M, Ishikawa O (2016) Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence. Ann Surg 264(6):1091–1097. https://doi.org/10.1097/sla.0000000000001547 CrossRefPubMed

33.

Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756. https://doi.org/10.1002/cncr.27636 CrossRefPubMed

34.

Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Michl M, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Niyazi M, Roeder F, Kirchner T, Werner J, Heinemann V, Boeck S (2016) Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 16(4):593–598. https://doi.org/10.1016/j.pan.2016.03.016 CrossRefPubMed

35.

Yamashita K, Miyamoto A, Hama N, Asaoka T, Maeda S, Omiya H, Takami K, Doki Y, Mori M, Nakamori S (2015) Survival impact of pulmonary metastasis as recurrence of pancreatic ductal adenocarcinoma. Dig Surg 32(6):464–471. https://doi.org/10.1159/000439545 CrossRefPubMed

36.

Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS (2014) Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford) 16(1):34–39. https://doi.org/10.1111/hpb.12058 CrossRef

37.

Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH (2012) Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16(9):1696–1704. https://doi.org/10.1007/s11605-012-1912-8 CrossRefPubMed

38.

Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L (2015) Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 6(34):36903–36910. https://doi.org/10.18632/oncotarget.5054 CrossRefPubMedPubMedCentral

39.

Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267(5):936–945. https://doi.org/10.1097/sla.0000000000002234 CrossRefPubMed

Title: Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma
Authors: Kenji Nakagawa
Takahiro Akahori
Satoshi Nishiwada
Minako Nagai
Kota Nakamura
Toshihiro Tanaka
Tetsuro Tamamoto
Chiho Ohbayashi
Masatoshi Hasegawa
Kimihiko Kichikawa
Naoya Ikeda
Masayuki Sho
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 6/2018
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-018-1709-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Implementation of robotic rectal surgery training programme: importance of standardisation and structured training

How we do it: totally laparoscopic complete mesocolon excision for splenic flexure cancer

Intensive perioperative rehabilitation improves surgical outcomes after pancreaticoduodenectomy

Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms

Trans-infundibular choledochoscopy: a method for accessing the common bile duct in complex cases

The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation